🚨 🚨 🚨 📢
$SPX $SPY $QQQ $VIX $VVIX $AAPL $NVDA $IWM
Tonight's TA report is now available.
Today we locked in 115%+ gains on our $NVDA Calls loaded last Friday and rolled the position. We're now riding the remainder risk-free into June 18th OpEx while #fintwit chases the biggest single-day $NVDA rally since February 2025. 😂
Inside tonight's report:
🌕 Full Moon volatility analysis
SPX, SPY, QQQ, IWM technical breakdown
$VIX and & VVIX setup
🍏 AAPL exhaustion signals
NVDA post-earnings / X Dividend roadmap.
Use the link below for access to tonight's report and positioning analysis...
Or continue trading blindfolded and let CNBC pick your entries. 👇
https://t.co/h1D2FmzgIc
Gold moving up as stocks and bonds sell off is a notable change in the intermarket action.
Only one day so don't want to read too much into it, but worth keeping an eye on.
The $VIX closed at 15.98, indicating an implied one day move range of +/-1.01% & an implied one month move range of +/-4.62% for the S&P 500 $SPY
https://t.co/VotF0m0L8V
This pain will soon be behind you. The struggle will be a thing of the past. Tables are turning sooner than you can think. Believe that good things will unravel for you. It is all aligning for you. You will attract the best in life.
$IMMX
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
Immix Biopharma surpassed the 50% enrollment milestone in its NEXICART-2 clinical trial, evaluating NXC-201, a sterically-optimized CAR-T therapy for relapsed/refractory AL Amyloidosis.
The company is advancing toward its goal of achieving the first FDA-approved cell therapy Biologics License Application (BLA) for this orphan indication, where currently no FDA-approved treatments exist. The trial's interim results were presented at ASCO 2025 by Heather Landau, MD, of Memorial Sloan Kettering Cancer Center, with growing interest from clinicians and patients following the presentation.
https://t.co/p5ttLILWi4
Joe Rogan just had the world's top human biologist on his podcast.
He revealed mind-blowing facts about health & longevity that 99% of people wouldn’t know...
Here are my top 8 takeaways:
@StockPatternPro I agree as well, but also a shoutout to some of your other contributors like Hawkeyes who deliver some great trade ideas. The group keeps growing and you keep it civilised 😀
$QQQ - ETF tested top of the channel and has gap to the downside from $481 to $475.80. looking for puts if that level breaks. next support below $475 if $470 / There is another gap to the downside from $454.80 to $445. on watch if we move lower to fill the gap. calls above $487 for a move towards $500
Today is a great day to set out on the journey towards your dreams. Let go of doubts and inhibitions. Stop giving yourself excuses for postponing it. Today is an awesome day to believe in yourself and fall in love with yourself. Celebrate every small progress. Create a happy life
🚨US growth is not a miracle, it is fully DEBT driven:
It took a MASSIVE $2.2 trillion in public debt to create $570 billion in GDP growth in 2024 (before revisions).
In other words, it took $3.9 of debt to generate $1 of economic growth.
CRAZY👇
https://t.co/vlghCZcVsg